FGF13-AS1 has been found to play a predominantly oncogenic role in breast cancer, reducing the glycolytic and stemness properties of breast cancer cells by inhibiting MYC expression through binding to insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs). This evidence concerns the gene MYC and breast carcinoma.